Injunction Denied Where Expert Testimony Shows Monetary Damages Were Subject to Quantification

Business Valuation Update BVLaw
Legal and Court Case Update
June 7, 2005

Access the Full Article

This article is available with a subscription to any of these products:
Already a subscriber?  Login
This article is also available for purchase. (627 words)   Add to Cart >>
Need help? Contact us:
1-503-479-8200 ext 2 or sales@bvresources.com
Aventis Pharma S.A. v. Novopharm Ltd.
2005 FC 815
Canada

Summary

In Aventis Pharma S.A. v. Novopharm Ltd., 2005 FC 815 (CanLII)(decided June 7, 2005), the Federal Court of Canada considered whether Aventis Pharma would suffer irreparable harm if an injunction prohibiting a generic drug from entering the market was not ...

See Also

Aventis Pharma S.A. v. Novopharm Ltd.

Full Text of Court Cases
June 7, 2005

In Aventis Pharma S.A. v. Novopharm Ltd., 2005 FC 815 (CanLII)(decided June 7, 2005), the Federal Court of Canada considered whether Aventis Pharma would suffer irreparable harm if an injunction prohibiting a generic drug from entering the market was not ...